Mayo Clinic, Mytonomy partner to develop breast cancer education videos

Mayo Clinic and Mytonomy, a provider of cloud-based patient education and information solutions, announced a collaboration to develop short videos addressing questions about breast cancer treatment.

The videos, which run from 30 seconds to three minutes, will address the most important questions and concerns regarding breast cancer treatment. By combining Mytonomy’s Patient Experience Cloud platform, which uses cognitive learning principles to drive patient engagement, and Mayo Clinic’s oncology experience, the two partners aim to improve clinical outcomes of patients with breast cancer at a lower cost.

“Mayo Clinic is a leader in cancer research, treatment and education. We are honored to be collaborating to improve the patient experience for cancer patients and their caregivers,” said Anjali Kataria, CEO of Mytonomy.

The microlearning videos will be available on mobile devices, so patients can view them anywhere. This feature may streamline the shared decision-making process between patients and providers. The library of videos will be available to other health systems through license through Mytonomy.

“We are pleased to be working with Mytonomy in this critically important aspect of healthcare – the patient experience,” said Sandhya Pruthi, MD, a Mayo Clinic internist and associate medical director of Mayo Clinic Global Business Solutions. “Recognizing how people learn today, and the unique circumstances of a cancer patient, we are excited to be combining our collective knowledge and expertise to foster patient engagement in ways that make sense for the 21st century patients and their families, and, ultimately, improve satisfaction and clinical outcomes.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.